Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

Tick bites are becoming a huge health care issue, as they can cause diseases like Lyme. Due to the recent surge in tick bites throughout the United States, it has become more important to know everything about the situation and the disease.

The Centers for Disease Control and Prevention (CDC) has already issued a warning about a surge in tick bite cases and possible Lyme disease in the Northeastern states, where tick-related emergency room visits have risen. The Midwest is the second most affected region.

Harvard Health states that about 90% of cases have been reported in 14 states: Connecticut, Maine, Virginia, Maryland, Massachusetts, Minnesota, New Jersey, New Hampshire, New York, Pennsylvania, Rhode Island, Vermont, Wisconsin, and West Virginia.

CDC reports ER visits related to tick bites hit their highest levels for spring since 2017. The United States has been fighting with tick-related issues for decades. The nation sees an estimated 476,000 people treated for Lyme disease each year.

Also Read: The Mystery Behind Trump’s Hair-Loss Drug And The Bigger Health Questions It Raises

What Is Lyme Disease?

Lyme disease is caused by a bacterium called Borrelia burgdorferi. This infectious disease is spread by infected ticks. The most common cause of these diseases in humans is bites from blacklegged ticks, though other variants can also be carriers. The Harvard Health says that most patients do not remember being bitten by a tick.

Also Read: Why Thousands Of Black Men In The UK Are Now Being Invited For Prostate Cancer Screening?

Unique Symptoms Of Lyme Disease

Heart Problems

Lyme can impact the cardiac, neurologic, and rheumatologic systems. The CDC says that 1 out of 100 patients has Lyme bacteria in their heart tissues. The condition is also called Lyme carditis.

Brain Fog

Advanced brain imaging shows that Lyme disease brain fog is real. It can lead to various effects, including difficulty focusing, thinking, reading, and absorbing information.

Bell's Palsy

There are 12 essential nerves, also known as the cranial nerves, that originate in the brain and play a crucial role in sensory functions and movements in the different parts of the head, face, neck, and torso. Lyme disease can also affect those nerves, leading to Bell's Palsy.

Eye Problems

Lyme can cause sudden vision loss, damage to the optic nerve, and neurotrophic keratitis. Other symptoms include blurry vision, eye floaters, tearing, and extreme sensitivity to light.

Hearing Problems

The most common Lyme-related hearing issues are tinnitus, vertigo and dizziness, headache, and unilateral sensorineural hearing or hearing loss in one ear.

Arthritis

The disease can cause swollen knees, a low-grade fever, or a limp. It usually starts in the fourth week after being bitten.

Fatigue

This is not just any fatigue, but a weakness that is debilitating. People with a history of Lyme were 8 to 15 times more likely to report severe or moderate fatigue than those who have never had the disease.

President Donald Trump's recent physical examination has been in the news, and now it is about a drug that was omitted in the test, which is making headlines. This very drug is raising questions about the health condition of President Trump, as he has been taking this drug for years. This medication is finasteride, a generic name for Propecia, which is a hair loss drug.

President Trump's recent test report at Walter Reed National Military Medical Center contains a list of drugs that he takes, but in that list, one important name was missing, and that is his hair loss drug, Propecia. According to The Washington Post, when they asked officials if the president still takes that drug, the White House said it was not obligated to reveal the full range of medications the president was taking.

The White House said, “The current report reflects all medications deemed clinically relevant to disclose at this time.” It added, “No additional undisclosed conditions or procedures materially affecting his health status were omitted from this report.”

Though even after the statement of the White House, experts are still questioning his health condition and the hair loss drug. Robert Klitzman, a psychiatrist who leads Columbia University’s master’s program in bioethics, said, “It raises significant questions of what else is possibly not being revealed.”

Steve Joffe, a physician and bioethicist at the University of Pennsylvania Perelman School of Medicine, said to the Post, “There’s a certain level of openness and disclosure that people have a right to expect from someone in whom they place such profound trust.”

President Trump's mysterious drug list, with many omissions, concerns experts as it lacks what matters the most.

Also Read: USDA Flags Suspected New World Screwworm Fly Detection in Texas

Why is Trump's Boasting About Cognitive Test Score Making Experts Question?

President Donald Trump is saying that he has achieved a full score in a very difficult test. He said, “Unlike other US Presidents, none of whom have ever taken an approved, high difficulty, Cognitive Test, I scored a perfect 30 out of 30, considered ‘extreme intelligence.’”

“In fact, this is my fourth such test, all PERFECT or 120 correct answers out of 120 questions asked! Anyone rarely gets a Perfect Score, especially when achieved four times in a row.” He wrote in his post.

He also demanded that the candidates for president and vice president should also go through this kind of test by saying, “In fact, this is my fourth such test, all PERFECT or 120 correct answers out of 120 questions asked! Anyone rarely gets a Perfect Score, especially when achieved four times in a row.”

Also Read: Why Thousands Of Black Men In The UK Are Now Being Invited For Prostate Cancer Screening?

Why Did Experts Question Repeated Testing?

Trump’s claims were immediately questioned by experts like Dr. Jonathan Reiner and Abby Phillip of CNN. They argued that repeated tests may not provide the same value. According to them, as the president had taken the test several times and the questions didn't change that much, it was easy. Other than that, the test is not designed to calculate intellect; it is more of a dementia screening test.

The recent hantavirus outbreak aboard the luxury ship MV Hondius, which drew global attention and raised concerns about the potential for wider spread, has highlighted the need for better therapeutics and vaccines.

The outbreak claimed three lives and infected 13 people. While those affected recovered from the infection, they had contracted the Andes strain, which carries a risk of human-to-human transmission. There is currently no specific antiviral drug or vaccine for the Andes virus.

Now, researchers writing in The Lancet Infectious Diseases have reported early promising results for tocilizumab as a treatment for severe hantavirus pulmonary syndrome (HPS).

The researchers said tocilizumab warrants further evaluation as a treatment for severe hantavirus pulmonary syndrome.

What Did The Study Find?

Also read: Can Hantavirus Spread Through Semen And Breast Milk? What Experts Say

The study is based on a case series involving 10 hantavirus patients treated at Hospital Zonal de Bariloche, Argentina, between June 1, 2024, and May 6, 2026.

Tocilizumab is an immunosuppressive medication used to treat severe inflammatory conditions, including severe COVID-19 and autoimmune diseases such as rheumatoid arthritis.

Researchers from San Carlos de Bariloche, Argentina, said that under an ethical framework allowing the emergency use of unproven medications outside clinical trials when no satisfactory alternatives exist, tocilizumab was administered to five eligible patients with laboratory-confirmed severe hantavirus pulmonary syndrome.

Five other patients received standard supportive care without Tocilizumab because they were too sick or the medication was unavailable when treatment was being considered. The case series represents the first descriptive report from a larger ongoing study.

Four of the five patients treated with Tocilizumab survived and were discharged from intensive care, whereas all five patients who did not receive Tocilizumab died shortly after admission to intensive care.

There is currently no approved vaccine or specific antiviral treatment for the Andes strain, underscoring the importance of further research into potential therapies such as tocilizumab.

However, the authors said, "the findings should not be interpreted as evidence for the implementation of routine use of Tocilizumab to treat severe hantavirus pulmonary syndrome, but they do support the need for urgent further research".

What Is Hantavirus?

According to the World Health Organization (WHO), hantaviruses are zoonotic viruses that naturally infect rodents and are occasionally transmitted to humans.

Globally, an estimated 100,000 to 200,000 hantavirus infections occur each year. The majority of cases are reported in Asia, particularly China. Most infections are sporadic or occur in small clusters linked to contact with infected rodents.

In humans, hantavirus infection can cause severe illness and death, although disease severity varies depending on the virus strain and geographical region.

Hantavirus Pulmonary Syndrome

Hantavirus pulmonary syndrome is a severe viral disease caused by the Andes virus, a type of hantavirus endemic in several regions of the Americas, including Argentina and Chile. In recent years, parts of Argentina have seen an increase in hantavirus cases.

The severe respiratory illness can rapidly become fatal. Reported fatality rates range from 20 per cent to 40 per cent, depending on the outbreak setting, quality of medical care, and surveillance capacity.

How Does Hantavirus Spread?

Hantavirus is primarily spread through contact with infected rodents, including exposure to:

• Urine
• Droppings
• Saliva
• Less commonly, scratches or bites from infected rodents